A Pooled Analysis of Eribulin in Breast Cancer
Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology, University of Leeds, discusses a pooled analysis of eribulin for the treatment of patients with breast cancer.
Clinical Pearls
Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology, University of Leeds, discusses apooled analysisof eribulin for the treatment of patients with breast cancer.
- In Study 301, eribulin showed a 6-week overall survival advantage over capecitabine in patients with locally advanced or metastatic breast cancer.
- A pooled analysis of Study 301 and EMBRACE was conducted to evaluate the efficacy of eribulin in subgroups.
- The pooled analysis confirmed the 2.5-month overall survival improvement across the entire population.
- A 2.9-month improvement in overall survival was observed in the HER2-negative population.
- A 4.7-month improvement in overall survival was observed in the triple-negative population.
Recent Videos
Related Content
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Article
Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
